Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
Open Access
- 14 May 2014
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 16 (7), 817-825
- https://doi.org/10.1002/ejhf.115
Abstract
Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing the hypothesis that the strategy of simultaneously blocking the renin–angiotensin–aldosterone system and augmenting natriuretic peptides with LCZ696 200 mg b.i.d. is superior to enalapril 10 mg b.i.d. in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction. Methods Key demographic, clinical and laboratory findings, along with baseline treatment, are reported and compared with those of patients in the treatment arm of the Studies Of Left Ventricular Dysfunction (SOLVD‐T) and more contemporary drug and device trials in heart failure and reduced ejection fraction. Results The mean age of the 8442 patients in PARADIGM‐HF is 64 (SD 11) years and 78% are male, which is similar to SOLVD‐T and more recent trials. Despite extensive background therapy with beta‐blockers (93% patients) and mineralocorticoid receptor antagonists (60%), patients in PARADIGM‐HF have persisting symptoms and signs, reduced health related quality of life, a low LVEF (mean 29 ± SD 6%) and elevated N‐terminal‐proB type‐natriuretic peptide levels (median 1608 inter‐quartile range 886–3221 pg/mL). Conclusion PARADIGM‐HF will determine whether LCZ696 is more beneficial than enalapril when added to other disease‐modifying therapies and if further augmentation of endogenous natriuretic peptides will reduce morbidity and mortality in heart failure and reduced ejection fraction.This publication has 32 references indexed in Scilit:
- Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)European Journal of Heart Failure, 2013
- Renin–Angiotensin Blockade Combined With Natriuretic Peptide System AugmentationCirculation: Heart Failure, 2013
- Treatment of Anemia with Darbepoetin Alfa in Systolic Heart FailureThe New England Journal of Medicine, 2013
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 2012
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Efficacy and Safety of Exercise Training in Patients With Chronic Heart FailureJAMA, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedemaBritish Journal of Pharmacology, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureThe New England Journal of Medicine, 2007